Amide Derivative Prodrugs for GI Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nonsteroidal anti-inflammatory (NSAI) drugs, particularly propionic acid derivatives, cause significant gastrointestinal toxicity, leading to adverse effects such as ulcers and ulcerative colitis, with existing solutions not adequately addressing the damage to the GI tract.
Innovation Solution
The synthesis of amide derivative prodrugs from NSAI drugs like dexketoprofen, ibuprofen, and flurbiprofen, where the carboxylic acid group is masked to form methyl esters and then reacted with trisubstituted methanamine, resulting in amide derivatives that are more stable and less toxic to the gastrointestinal system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If propionic acid derivatives of NSAI drugs are used, then anti-inflammatory effects are achieved, but gastrointestinal toxicity increases
Solution Approach 1:
The patent applies the intermediary principle by introducing a prodrug formulation where the active NSAI drug is masked within an amide derivative structure. This prodrug acts as an intermediary form that is less harmful to the GI tract during transit, and is then converted to the active drug form in the body, thus mediating between the need for anti-inflammatory efficacy and the reduction of gastrointestinal toxicity
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of the NSAI drug through amide derivative formation. This structural modification changes the physicochemical parameters of the drug molecule, specifically masking the carboxylic acid group to reduce GI irritation, while maintaining the core anti-inflammatory pharmacological activity through enzymatic conversion in vivo
2Object-affected harmful factors
If acidic groups in NSAI drugs are masked to form prodrugs, then gastrointestinal toxicity is reduced, but drug stability in simulated GI conditions increases (reducing activation)
Solution Approach 1:
The patent applies preliminary action by pre-modifying the NSAI drug into an amide derivative prodrug form before administration. This preliminary structural modification protects the drug from premature activation and degradation in the GI tract, allowing it to reach the target site intact and then be converted to the active form by bodily enzymes
Solution Approach 2:
The amide derivative structure serves as a stable intermediary form that protects the active drug from degradation in GI conditions while still allowing enzymatic conversion to the active form. This intermediary structure mediates between the need for stability during GI transit and the need for activation to exert therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amide derivatives exhibit reduced hydrolysis and increased stability in simulated GI tract conditions, potentially lowering gastrointestinal toxicity while maintaining anti-inflammatory effects, as demonstrated by hydrolysis studies at pH 1.2 and pH 6.8.
Implementation Method 1
formation of a methyl ester of the carboxylic acid group
Implementation Method 2
amidization of this methyl ester with trisubstituted methanamine
Implementation Method 3
hydrolysis studies at pH 1.2 and pH 6.8
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention presents a method for masking acidic groups existing in NSAI drugs to prevent or to reduce the hazards of NSAI drugs to GI (gastrointestinal) system. The developed method comprises production of new amide derivatives by methyl esterification of carboxylic acid groups which belong to NSAI drugs and then amidification of the same. The invention is also related to the amide derivatives of new NSAI drugs which are suitable for use as pro-drugs.